Xenetic Biosciences reports Q2 earnings meeting expectations, with EPS of ($0.83) and $0.73M revenue.

Xenetic Biosciences (NASDAQ: XBIO) reported Q2 earnings, meeting analyst expectations with an EPS of ($0.83) and revenue of $0.73M (vs. $0.54M est.). Shares traded down $0.14 to $3.15, with a market cap of $4.85M, P/E of -1.08, and beta of 2.29. The biopharmaceutical firm focuses on advancing personalized CAR T platform technology, XCART, for B-cell lymphoma treatment.

August 15, 2024
6 Articles

Further Reading